UK HealthCare

Markey study: Molecular tumor boards improve outcomes for patients with advanced cancer

The Molecular Tumor Board is codirected by Rachel Miller, M.D., and Jill Kolesar, Pharm.D. (photo taken in 2017) Mark Cornelison | UK Photo
The Molecular Tumor Board is co-directed by Rachel Miller, M.D., and Jill Kolesar, Pharm.D. (photo taken in 2017). Mark Cornelison | UK Photo.

LEXINGTON, Ky. (Sept. 22, 2022) — In a recent University of Kentucky Markey Cancer Center clinical trial, patients with advanced cancer experienced improved outcomes when their treatments were directed by a molecular tumor board.

Molecular tumor boards (MTB) are composed of an interdisciplinary team of medical experts who use tumor genomic analysis to help oncologists choose cancer therapies tailored to each patient’s individual needs. When a physician requests a MTB review, patients' tumors are tested for mutations using next-generation sequencing. The board then evaluates the report and may recommend three types of potential care: therapies for that patient's cancer type that are approved by the Food and Drug Administration (FDA), FDA-approved therapies in another tumor type and potential clinical trials.

Results published in JCO Precision Oncology Sept. 14 demonstrate that the MTB review process improves overall survival rates for patients with advanced cancer.

Patients participating in the phase II clinical trial received therapy directed by UK Markey Cancer Center’s MTB between 2017 and 2020.

The study provides important data that supports the clinical use of MTBs in cancer care, says study author Jill Kolesar, Pharm.D., a professor in UK’s College of Pharmacy who directs Markey’s Precision Medicine Center and co-directs the MTB.

“As personalized cancer therapies are quickly becoming approved for multiple molecular targets, MTBs may help oncologists choose the most effective therapy option,” said Kolesar. “The study suggests that the precision medicine expertise offered by a MTB can lead to better outcomes even for patients with advanced cancer who have already received treatment.”

All 93 enrolled patients had advanced cancer with tumors that had actionable mutations, or DNA mutations that can be targeted with an available treatment.

The study measured their progression-free survival, or the length of time during and after a treatment that a patient lives with cancer, but it does not get worse. By comparing the MTB-directed therapy with the patients’ immediately prior therapy, the study allowed patients to serve as their own control.

“When treated with MTB-directed therapy, most patients experienced improved progression-free survival compared with immediately prior treatment. MTB-directed targeted therapy may be a strategy to improve outcomes for patients with advanced cancer,” the study concludes.

Launched in 2016, the UK Markey Cancer Center MTB includes representation from medical oncology, surgical oncology, pathology, radiology, genetic counseling and clinical pharmacology.

By analyzing the molecular characteristics of cancer tumors on a case-by-case basis, the MTB also creates a cache of information to direct the development of new therapies and clinical trials that target the types of cancers found at Markey and throughout Kentucky.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA177558. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

As the state’s flagship, land-grant institution, the University of Kentucky exists to advance the Commonwealth. We do that by preparing the next generation of leaders — placing students at the heart of everything we do — and transforming the lives of Kentuckians through education, research and creative work, service and health care. We pride ourselves on being a catalyst for breakthroughs and a force for healing, a place where ingenuity unfolds. It's all made possible by our people — visionaries, disruptors and pioneers — who make up 200 academic programs, a $476.5 million research and development enterprise and a world-class medical center, all on one campus.   

In 2022, UK was ranked by Forbes as one of the “Best Employers for New Grads” and named a “Diversity Champion” by INSIGHT into Diversity, a testament to our commitment to advance Kentucky and create a community of belonging for everyone. While our mission looks different in many ways than it did in 1865, the vision of service to our Commonwealth and the world remains the same. We are the University for Kentucky.